137 related articles for article (PubMed ID: 34719159)
21. Mutation of von Hippel-Lindau tumor suppressor gene in a sporadic endolymphatic sac tumor.
Hamazaki S; Yoshida M; Yao M; Nagashima Y; Taguchi K; Nakashima H; Okada S
Hum Pathol; 2001 Nov; 32(11):1272-6. PubMed ID: 11727270
[TBL] [Abstract][Full Text] [Related]
22. CAIX and pax-8 Commonly Immunoreactive in Endolymphatic Sac Tumors: A Clinicopathologic Study of 26 Cases with Differential Considerations for Metastatic Renal Cell Carcinoma in von Hippel-Lindau Patients.
Thompson LDR; Magliocca KR; Andreasen S; Kiss K; Rooper L; Stelow E; Wenig BM; Bishop JA
Head Neck Pathol; 2019 Sep; 13(3):355-363. PubMed ID: 30291511
[TBL] [Abstract][Full Text] [Related]
23. Expression of renal cell markers and detection of 3p loss links endolymphatic sac tumor to renal cell carcinoma and warrants careful evaluation to avoid diagnostic pitfalls.
Jester R; Znoyko I; Garnovskaya M; Rozier JN; Kegl R; Patel S; Tran T; Abedalthagafi M; Horbinski CM; Richardson M; Wolff DJ; Lapadat R; Moore W; Rodriguez FJ; Mull J; Olar A
Acta Neuropathol Commun; 2018 Oct; 6(1):107. PubMed ID: 30340515
[TBL] [Abstract][Full Text] [Related]
24. [Endolymphatic sac tumor with von Hippel-Lindau disease: report of two cases with testing of von Hippel-Lindau gene].
Su Y; Shen WD; Wang CC; Han WJ; Liu J; Hou ZH; Song ZG; Huang DL; Han DY; Yang SM
Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2013 Nov; 48(11):913-8. PubMed ID: 24444636
[TBL] [Abstract][Full Text] [Related]
25. The relationship of erythropoietin overexpression with von Hippel-Lindau tumour suppressor gene mutations between hypoxia-inducible factor-1α and -2α in sporadic clear cell renal carcinoma.
Gong K; Zhang N; Zhang K; Na Y
Int J Mol Med; 2010 Dec; 26(6):907-12. PubMed ID: 21042786
[TBL] [Abstract][Full Text] [Related]
26. Constitutive activation of hypoxia-inducible genes related to overexpression of hypoxia-inducible factor-1alpha in clear cell renal carcinomas.
Wiesener MS; Münchenhagen PM; Berger I; Morgan NV; Roigas J; Schwiertz A; Jürgensen JS; Gruber G; Maxwell PH; Löning SA; Frei U; Maher ER; Gröne HJ; Eckardt KU
Cancer Res; 2001 Jul; 61(13):5215-22. PubMed ID: 11431362
[TBL] [Abstract][Full Text] [Related]
27. Expression of VHL and HIF-1α and Their Clinicopathologic Significance in Benign and Malignant Lesions of the Gallbladder.
Yang Z; Yang Z; Xiong L; Huang S; Liu J; Yang L; Miao X
Appl Immunohistochem Mol Morphol; 2011 Dec; 19(6):534-9. PubMed ID: 21415706
[TBL] [Abstract][Full Text] [Related]
28. Role of VHL, HIF1A and SDH on the expression of miR-210: Implications for tumoral pseudo-hypoxic fate.
Merlo A; Bernardo-Castiñeira C; Sáenz-de-Santa-María I; Pitiot AS; Balbín M; Astudillo A; Valdés N; Scola B; Del Toro R; Méndez-Ferrer S; Piruat JI; Suarez C; Chiara MD
Oncotarget; 2017 Jan; 8(4):6700-6717. PubMed ID: 28036268
[TBL] [Abstract][Full Text] [Related]
29. [The expression of hypoxia inducible factor-1,2 alpha in sporadic clear cell renal cell carcinoma and their relationships to the mutations of von Hippel-Lindau gene].
Gong K; Zhang N; Na X; Wu G; Yang XY; Xin DQ; Na YQ
Zhonghua Wai Ke Za Zhi; 2005 Mar; 43(6):390-3. PubMed ID: 15854350
[TBL] [Abstract][Full Text] [Related]
30. The role of aberrant VHL/HIF pathway elements in predicting clinical outcome to pazopanib therapy in patients with metastatic clear-cell renal cell carcinoma.
Choueiri TK; Fay AP; Gagnon R; Lin Y; Bahamon B; Brown V; Rosenberg JE; Hutson TE; Baker-Neblett KL; Carpenter C; Liu Y; Pandite L; Signoretti S
Clin Cancer Res; 2013 Sep; 19(18):5218-26. PubMed ID: 23881929
[TBL] [Abstract][Full Text] [Related]
31. Renal cancer cells lacking hypoxia inducible factor (HIF)-1alpha expression maintain vascular endothelial growth factor expression through HIF-2alpha.
Shinojima T; Oya M; Takayanagi A; Mizuno R; Shimizu N; Murai M
Carcinogenesis; 2007 Mar; 28(3):529-36. PubMed ID: 16920734
[TBL] [Abstract][Full Text] [Related]
32. Vascular endothelial growth factor production is induced by histone deacetylase 1 and suppressed by von Hippel-Lindau protein in HaCaT cells.
Reynoso-Roldán A; Roldán ML; Cancino-Diaz JC; Rodríguez-Martínez S; Cancino-Diaz ME
Clin Invest Med; 2012 Dec; 35(6):E340-50. PubMed ID: 23217559
[TBL] [Abstract][Full Text] [Related]
33. Expression of HIF-1 and ubiquitin in conventional renal cell carcinoma: relationship to mutations of the von Hippel-Lindau tumor suppressor gene.
Hughson MD; He Z; Liu S; Coleman J; Shingleton WB
Cancer Genet Cytogenet; 2003 Jun; 143(2):145-53. PubMed ID: 12781449
[TBL] [Abstract][Full Text] [Related]
34. VHL and HIF-1α: gene variations and prognosis in early-stage clear cell renal cell carcinoma.
Lessi F; Mazzanti CM; Tomei S; Di Cristofano C; Minervini A; Menicagli M; Apollo A; Masieri L; Collecchi P; Minervini R; Carini M; Bevilacqua G
Med Oncol; 2014 Mar; 31(3):840. PubMed ID: 24446253
[TBL] [Abstract][Full Text] [Related]
35. Tuberous sclerosis complex protein 1 expression is affected by VHL Gene alterations and HIF-1α production in sporadic clear-cell renal cell carcinoma.
Damjanovic SS; Ilic BB; Beleslin Cokic BB; Antic JA; Bankovic JZ; Milicevic IT; Rodic GS; Ilic DS; Todorovic VN; Puskas N; Tulic CD
Exp Mol Pathol; 2016 Dec; 101(3):323-331. PubMed ID: 27845047
[TBL] [Abstract][Full Text] [Related]
36. Vestibular Function in Children With Von Hippel-Lindau Disease.
Fatih Turgut N; Crunkhorn R; Iqbal J; Dasgupta S
J Int Adv Otol; 2021 Jul; 17(4):361-367. PubMed ID: 34309559
[TBL] [Abstract][Full Text] [Related]
37. Over-expression of hypoxia-inducible factor 1 alpha in ovarian clear cell carcinoma.
Lee S; Garner EI; Welch WR; Berkowitz RS; Mok SC
Gynecol Oncol; 2007 Aug; 106(2):311-7. PubMed ID: 17532031
[TBL] [Abstract][Full Text] [Related]
38. Prognostic Value of the VHL, HIF-1α, and VEGF Signaling Pathway and Associated MAPK (ERK1/2 and ERK5) Pathways in Clear-Cell Renal Cell Carcinoma. A Long-Term Study.
Salinas-Sánchez AS; Serrano-Oviedo L; Nam-Cha SY; Roche-Losada O; Sánchez-Prieto R; Giménez-Bachs JM
Clin Genitourin Cancer; 2017 Dec; 15(6):e923-e933. PubMed ID: 28624320
[TBL] [Abstract][Full Text] [Related]
39. Coexpression of erythropoietin and its receptor in endolymphatic sac tumors.
Vogel TW; Vortmeyer AO; Lubensky IA; Lee YS; Furuta M; Ikejiri B; Kim HJ; Lonser RR; Oldfield EH; Zhuang Z
J Neurosurg; 2005 Aug; 103(2):284-8. PubMed ID: 16175858
[TBL] [Abstract][Full Text] [Related]
40. Endolymphatic sac tumors: clinical outcome and management in a series of 9 cases.
Timmer FC; Neeskens LJ; van den Hoogen FJ; Slootweg PJ; Dunnebier EA; Pauw BK; Mulder JJ; Cremers CW; Kunst HP
Otol Neurotol; 2011 Jun; 32(4):680-5. PubMed ID: 21451430
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
